At ACC’s 2021 annual meeting, The Lancet Women and Cardiovascular Disease Commission, led by Roxana Mehran, MD, Mount Sinai Endowed Professor of Medicine, and Population Health Science and Policy, and Director of Interventional Cardiovascular Research and Clinical Trials at the Icahn School of Medicine at Mount Sinai, issued major new recommendations aimed at fully understanding and reducing the global burden of heart disease in women.
“The Lancet Women and Cardiovascular Disease Commission” developed specific, worldwide recommendations for heart disease prevention and treatment based on an unprecedented global review and analysis. The recommendations included expanding education and health programs, and research on women’s heart disease. The commission’s report was published in the May 16 issue of The Lancet, and simultaneously presented at the American College of Cardiology’s Annual Scientific Sessions.
Cardiovascular disease is the leading cause of death for women around the world. There are roughly 275.2 million women diagnosed with heart disease worldwide, and 20.8 million in the United States, a majority of these cases are preventable.
The Lancet Women and Cardiovascular Disease Commission report was authored by 17 senior experts in the field from 11 countries. Their goals were to address current gaps in knowledge among physicians and patients, outline region-specific recommendations for reducing the burden of heart disease in women, and ultimately improve the outcomes of women with cardiovascular disease by 2030.
Director of Interventional Cardiovascular Research and Clinical Trials Zena and Michael A. Wiener Cardiovascular Institute Mount Sinai Endowed Professor of Medicine (Cardiology) Icahn School of Medicine at Mount Sinai